OBJECTIVE: To explore the occurrence and characteristics of aggressive multiple sclerosis (AMS) in adult-onset multiple sclerosis (MS) patients. METHODS: Prospectively collected data (1980-2009) from British Columbia, Canada, were retrospectively analysed. AMS was defined in three different ways (AMS1, 2 and 3): 'AMS1'--confirmed Expanded Disability Status Scale (EDSS) ≥ 6 within 5 years of MS onset; 'AMS2'--confirmed EDSS ≥ 6 by age 40; and 'AMS3'--secondary progressive MS within 3 years of a relapsing-onset course. Three respective 'non-aggressive' MS comparison cohorts were selected. Patients' characteristics were compared between aggressive and non-aggressive cohorts using multivariable logistic regression, with findings expressed as adjusted OR (AOR) and 95% CI. RESULTS: Application of the three definitions to the source population of 5891 patients resulted in 235/4285 (5.5%) patients fulfilling criteria for AMS1 (59.6% were female; 74.5% had relapsing-onset MS), 388/2762 (14.0%) for AMS2 (65.2% were female; 92.8% had relapsing-onset MS) and 195/4918 (4.0%) patients for AMS3 (61.0% were female). Compared to the respective control cohorts, those with AMS were more likely to be male (AOR=1.5, 95% CI 1.1 to 2.0 (AMS1); 1.6, 95% CI 1.3 to 2.1 (AMS2); 1.8, 95% CI 1.3 to 2.4 (AMS3)), older at MS symptom onset (AOR=1.1; 95% CI 1.1 to 1.1 (AMS1 and AMS3)) and have primary progressive MS (AOR=2.3, 95% CI 1.6 to 3.3 (AMS1); 2.7, 95% CI 1.7 to 4.4 (AMS2)). CONCLUSIONS: AMS was identified in 4-14% of patients, depending on the definition used. Although there was a relative preponderance of men and primary progressive MS presenting with AMS, the majority of patients were still women and those with relapsing-onset MS.
OBJECTIVE: To explore the occurrence and characteristics of aggressive multiple sclerosis (AMS) in adult-onset multiple sclerosis (MS) patients. METHODS: Prospectively collected data (1980-2009) from British Columbia, Canada, were retrospectively analysed. AMS was defined in three different ways (AMS1, 2 and 3): 'AMS1'--confirmed Expanded Disability Status Scale (EDSS) ≥ 6 within 5 years of MS onset; 'AMS2'--confirmed EDSS ≥ 6 by age 40; and 'AMS3'--secondary progressive MS within 3 years of a relapsing-onset course. Three respective 'non-aggressive' MS comparison cohorts were selected. Patients' characteristics were compared between aggressive and non-aggressive cohorts using multivariable logistic regression, with findings expressed as adjusted OR (AOR) and 95% CI. RESULTS: Application of the three definitions to the source population of 5891 patients resulted in 235/4285 (5.5%) patients fulfilling criteria for AMS1 (59.6% were female; 74.5% had relapsing-onset MS), 388/2762 (14.0%) for AMS2 (65.2% were female; 92.8% had relapsing-onset MS) and 195/4918 (4.0%) patients for AMS3 (61.0% were female). Compared to the respective control cohorts, those with AMS were more likely to be male (AOR=1.5, 95% CI 1.1 to 2.0 (AMS1); 1.6, 95% CI 1.3 to 2.1 (AMS2); 1.8, 95% CI 1.3 to 2.4 (AMS3)), older at MS symptom onset (AOR=1.1; 95% CI 1.1 to 1.1 (AMS1 and AMS3)) and have primary progressive MS (AOR=2.3, 95% CI 1.6 to 3.3 (AMS1); 2.7, 95% CI 1.7 to 4.4 (AMS2)). CONCLUSIONS:AMS was identified in 4-14% of patients, depending on the definition used. Although there was a relative preponderance of men and primary progressive MS presenting with AMS, the majority of patients were still women and those with relapsing-onset MS.
Authors: Ruth Ann Marrie; Charles N Bernstein; Christine A Peschken; Carol A Hitchon; Hui Chen; Randy Fransoo; Allan Garland Journal: Neurology Date: 2014-05-07 Impact factor: 9.910
Authors: Thomas F Scott; Troy Desai; Chris Hackett; Edward J Gettings; Teresa Hentosz; Wisam Elmalik; Carol J Schramke Journal: Int J MS Care Date: 2019-12-05
Authors: J Das; J A Snowden; J Burman; M S Freedman; H Atkins; M Bowman; R K Burt; R Saccardi; C Innocenti; S Mistry; P J Laud; H Jessop; B Sharrack Journal: Mult Scler Date: 2021-02-10 Impact factor: 6.312
Authors: Ulrike W Kaunzner; Gaurav Kumar; Gulce Askin; Susan A Gauthier; Nancy N Nealon; Timothy Vartanian; Jai S Perumal Journal: Neuropsychiatr Dis Treat Date: 2016-08-01 Impact factor: 2.570
Authors: Tjalf Ziemssen; Ann D Bass; Regina Berkovich; Giancarlo Comi; Sara Eichau; Jeremy Hobart; Samuel F Hunter; Christopher LaGanke; Volker Limmroth; Daniel Pelletier; Carlo Pozzilli; Sven Schippling; Livia Sousa; Anthony Traboulsee; Bernard M J Uitdehaag; Bart Van Wijmeersch; Zia Choudhry; Nadia Daizadeh; Barry A Singer Journal: CNS Drugs Date: 2020-09 Impact factor: 5.749
Authors: Elia Gil-Varea; Elena Urcelay; Carles Vilariño-Güell; Carme Costa; Luciana Midaglia; Fuencisla Matesanz; Alfredo Rodríguez-Antigüedad; Jorge Oksenberg; Laura Espino-Paisan; A Dessa Sadovnick; Albert Saiz; Luisa M Villar; Juan Antonio García-Merino; Lluís Ramió-Torrentà; Juan Carlos Triviño; Ester Quintana; René Robles; Antonio Sánchez-López; Rafael Arroyo; Jose C Alvarez-Cermeño; Angela Vidal-Jordana; Sunny Malhotra; Nicolas Fissolo; Xavier Montalban; Manuel Comabella Journal: J Neuroinflammation Date: 2018-09-14 Impact factor: 8.322
Authors: Simon Thebault; Daniel R Tessier; Hyunwoo Lee; Marjorie Bowman; Amit Bar-Or; Douglas L Arnold; Harold L Atkins; Vincent Tabard-Cossa; Mark S Freedman Journal: Neurol Neuroimmunol Neuroinflamm Date: 2019-08-08